

BIOGRAPHY



Name: F. Blaine Hollinger, M.D.

Position: Professor of Medicine, Molecular Virology & Epidemiology; Director, Eugene B. Casey Hepatitis Research Center

Institution: Baylor College of Medicine
Houston, Texas, USA

BRIEF INTRODUCTION

Dr. F. Blaine Hollinger has been actively involved in hepatitis research since joining the Department of Molecular Virology and Microbiology at Baylor College of Medicine in Houston, Texas in 1968 and the Department of Medicine (GI/Baylor Liver Center) in 1981. He is currently Professor of Medicine, Molecular Virology & Epidemiology and Director of the Eugene B. Casey Hepatitis Research Center. He is a Fellow of the IDSA, the AGA, the ACG, and the AASLD. He is listed in the Marquis Who's Who in America and the American Men and Women of Science publications and is a Rhodes Scholar candidate. He has been an advisor and consultant on program projects, grants, and contracts related to viral hepatitis and drug therapy for the National Institutes of Health and the Food and Drug Administration (FDA) and a consultant to the Transfusion Transmitted Diseases Committee of the AABB. He served on the Blood Products Advisory Committee (BPAC) for the FDA becoming its Chairman in 1997 and again in 2010 for which he was presented with the Advisory Committee Service Award on each occasion.

Dr. Hollinger is an experienced researcher and hepatologist who has engaged in a number of national multicenter clinical trials and basic scientific projects related to viral hepatitis over the past 40 years. He has published over 275 articles, books and chapters in this field that includes the characterization and diagnosis of viral hepatitis agents, development of sensitive immunological assays, prophylaxis of hepatitis A and B, vaccine development, therapy of hepatitis B and C, studies on the immunopathogenesis and natural history of viral hepatitis, and the epidemiology of blood-borne pathogens and posttransfusion hepatitis. His current research interests are to determine how chronic HCV infection disrupts the insulin signaling pathway and interferes with interferon response, to study the effect of HBx on viral replication that might lead to the development of a novel antiviral drug inhibitor and the prevention of hepatocellular carcinoma, and to exploit the use of a chimeric, immunodeficient mouse model engrafted with human hepatocytes to evaluate new therapeutic targets for HBV and HCV and to determine the role of occult hepatitis B in transfusion medicine. His clinic responsibilities include all aspects of acute and chronic liver disease in the Baylor St. Luke's Liver Center.